The multi‑year renewal strengthens ABL’s integrated platform, improving revenue visibility and supporting the Group’s ...

If last year’s pharma ad showing during the Super Bowl drove buzzy conversation and a touch of controversy, the lasting impression pharma marketers made on consumers during Sunday’s Super Bowl LX took ...

Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant ...

Two years ago, a GLP-1 prescription could cost an uninsured patient more than $1,000 a month. Today, Novo Nordisk’s NOVO.B-0.29%decrease; red down pointing triangle Wegovy pill starts at just $149 ...

The Trump administration is delaying the release of TrumpRx, an online platform that lets people buy prescription drugs directly from pharmaceutical companies at a discount, according to Politico.

India-based Sun Pharmaceutical Industries Ltd is reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN), a U.S.-based women's healthcare company. If it goes through, the deal that ...

Drug development is notoriously failure-prone. Only one in every ten drug candidates that enter human trials eventually goes onto the market. Turning a promising molecule into a useful medicine ...

CloudRock’s headcount will have doubled since GCP’s initial investment to create a business on track to generate around £40m revenue GCP invested in CloudRock in 2024 CloudRock is a global HR and ...

After months of threats, President Trump eased up pressure on drugmakers late last year. That’s all it took for investors to notice that the beaten-down sector was actually growing just fine. Talk of ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A South Carolina pharmaceutical ...

Looking back on 2025, a lot happened in the world of healthcare. This year was largely defined by the arrival of the second Trump administration, armed with tariff threats, unorthodox views about ...

For pharmaceutical firms, watching the lucrative patents on their top-selling drugs expire has long been part of the business cycle. There’s enormous pressure to find ways of covering the shortfall.